Standard BioTools Terminates Its Previously Announced Agreement To Sell Its Mass Cytometry Business To Multiplex Bio; Co. Enters Into A Definitive Agreement To Sell Its Mass Cytometry Business To Element Biosystems For $5.5M In Cash Payable

Standard BioTools Inc. (NASDAQ:LAB) ("Standard BioTools" or the "Company") today announced the following updates in connection with the Company’s previously announced merger with Treeline Biosciences, Inc. ("Treeline"):

Standard BioTools terminated its previously announced agreement to sell its Mass Cytometry Business to Multiplex Bio and entered into a definitive agreement to sell its Mass Cytometry business to Element Biosystems, LLC ("Element"), an acquisition vehicle formed by GMT Venture Partners, LLC ("GMT Venture") for $5.5 million in cash payable at closing, subject to customary adjustments.